IMPORTANCE Dual anti-platelet therapy represents standard care for treating patients with ST-segment elevation myocardial infarction (STEMI). Ticagrelor is a direct-acting P2Y12 inhibitor and, unlike clopidogrel and prasugrel, does not require metabolic activation.
T icagrelor is an orally administered cyclopentyl triazolopyrimidine that reversibly and directly inhibits the platelet P2Y12 receptor 1 and does not require metabolic activitation for inhibition of platelet aggregation (IPA). 2 Given the higher risk of peri-procedural thrombotic events in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI), there is a need to achieve IPA more promptly. Nevertheless, when administering a P2Y12 inhibitor in patients with STEMI, the time to peak IPA may take several hours. 3 Although platelet reactivity is a surrogate, the delay in platelet inhibition in response to a ticagrelor loading dose (LD) in patients with STEMI has been related to several factors and primarily to an impaired intestinal absorption. 4 Several studies have tried to overcome this problem with increasing the dosing regimen and crushing tablets. 5 Although chewing ticagrelor has been shown to be more efficient for patients with IPA with acute coronary syndrome/non-STEMI, 6 to our knowledge, there are no studies that have specifically assessed the efficacy and safety of chewing ticagrelor in patients with STEMI. The aim of this study was to investigate whether chewing ticagrelor is associated with more favorable platelet inhibitory effects compared with the conventional way of swallowing whole tablets in patients with STEMI undergoing PPCI.
Methods
This prospective study was conducted from May to October 2016 and comprised 50 consecutive patients with STEMI who underwent PPCI. Patient treatment has been described previously. 6 In brief, all patients were treated with a ticagrelor LD (180 mg per day) and aspirin (100 mg per day). On admission, patients were randomized to either the chewing group (patients were asked to actively chew the tablets and not to swallow them and did not receive water) or the traditional swallowing group (standard group of the 180-mg ticagrelor LD). Patients then continued to receive oral ticagrelor (90 mg twice daily) in the conventional swallowing way. Exclusion criteria have been described previously. 6 Baseline characteristics and in-hospital therapy were prospectively recorded. The study was approved by the local institutional review board, and patients provided written informed consent. The full trial protocol is available in Supplement 1.
Platelet Reactivity Testing
Blood samples for platelet reactivity were collected at baseline (before ticagrelor LD), 30 minutes, 1 hour, and 4 hours after ticagrelor LD. Platelet reactivity was performed using VerifyNow (Accumetrics) and was reported in P2Y12 reaction units (PRU). 7 High treatment-related platelet reactivity (HPR)
was defined as a PRU of more than 208. 8 All patients were then treated at the discretion of the treating physicians.
End Points
The primary end point was residual platelet reactivity by PRU at 1 hour after ticagrelor LD. Secondary end points were (1) platelet reactivity at each point; (2) rates of HPR; (3) major adverse cardiac and cerebrovascular events (death, myocardial infarction, urgent revascularization, stroke/transient ischemic attack) at 30 days; (4) major or minor bleeding (using Thrombolysis in Myocardial Infarction criteria); and (5) occurrence of dyspnea and/or symptomatic bradycardia.
Statistical Analysis
The primary and secondary end points were assessed based on an intention-to-treat basis. Assuming an absolute 15% dif- Meaning In patients with ST-segment elevation myocardial infarction, chewing a loading dose of ticagrelor, 180 mg, may be warranted.
ference in the PRU between the 2 groups at 1 hour after ticagrelor LD with a common SD of 10%, 20 patients would need to be enrolled in each arm to obtain a 95% power and a 2-sided α of .05. Considering a dropout rate of approximately 5%, we estimated that a total of 50 patients would need to be randomized to ensure complete data availability for analysis. The t test was used for evaluating the difference in prespecified end points. If the assumption of normality was violated, a nonparametric test (Mann-Whitney U or Wilcoxon signed rank test) was performed. The effect of treatment allocation on the clinical secondary end points was assessed using Cox proportional hazards regression analysis.
Results

Patient Population
A patient enrollment flow diagram is presented in Figure 1 . Baseline characteristics, as well as culprit vessel distribution, multivessel (≥2) disease, and thrombolysis in myocardial infarction flow after PPCI, are presented in the Figure 2) . Rates of HPR were markedly reduced in the chewing group compared with the standard group (eFigure in Supplement 2). Moreover, HPR was present in approximately half of the standard group at 1 hour.
Follow-up at 30 Days
The rate of major adverse cardiac and cerebrovascular events at 30 days was low, occurring in 1 patient in the chewing group 
Discussion
To our knowledge, this is the first investigation to show that, in patients with STEMI undergoing PPCI, chewing an LD of ticagrelor, 180 mg, was associated with enhanced platelet inhibitory effects compared with standard ticagrelor administration, particularly in the early hours after drug administration. Notably, reduced platelet reactivity with chewing ticagrelor was observed as early as 30 minutes after drug administration. Accordingly, chewing ticagrelor led to a significant reduction in HPR rates, particularly at 1 hour after LD. In patients with STEMI and particularly in patients undergoing PPCI, the delayed onset of action to oral P2Y12 receptor inhibitors can last for several hours and cause an increased risk of thrombotic complications during and after PPCI. 9, 10 Results of our trial suggest that chewing ticagrelor offers either a faster absorption via the mucosa and/or a faster absorption in the stomach. The use of morphine has also been associated with a further delay in drug and thienopyridine absorption.
11
Chewing ticagrelor could overcome the disadvantages of drug absorption via the gastrointestinal tract particularly during the first crucial hours of STEMI.
Limitations and Clinical Implications
Our study lacks pharmacokinetic confirmation, and therefore the results should be interpreted with caution. Although platelet reactivity has been associated with ischemic outcomes, 12,13 it must be acknowledged that it is a surrogate outcome. Indeed, our single-center study included a relatively small sample size and therefore was not powered to assess clinical outcomes
Conclusions
Chewing an LD of ticagrelor, 180 mg, in patients with STEMI is feasible and facilitates a faster and more pronounced early IPA compared with a standard oral LD. Larger studies are warranted to investigate if our pharmacodynamics findings translate into improved clinical outcomes in patients with STEMI. Author Contributions: Dr Asher had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or 
Background
The P2Y12-receptor amplifies platelet activation in response to ADP (1).
Dual anti-platelet therapy (DAPT) with a P2Y12-receptor antagonist and aspirin is the standard of care for the treatment of ischemic patients (2-5). The coadministration of a P2Y12-receptor inhibitor and aspirin reduces platelet reactivity to a greater extent than each drug can achieve separately (6-7).
Clopidogrel is a second-generation thienopyridine. It is orally administered, and requires two metabolic transformations to effect platelets (8) . The thirdgeneration thienopyridine prasugrel is also a prodrug, but requires only a singlestep oxidation in the liver by CYP to become active (9) . The metabolic conversion of prasugrel is more efficient, and results in higher in vivo availability (10) .
Ticagrelor is also administrated orally but in contrast to clopidogrel and prasugrel is not a prodrug and hence does not require activation (9) . Ticagrelor directly inhibits the platelet P2Y12-receptor through allosteric modulation (9).
In the PLATO trial, ticagrelor therapy was also superior to clopidogrel treatment in patients with recurrent cardiovascular events, STEMI, diabetes mellitus, chronic kidney disease, with or without loss-of-function polymorphisms in CYP2C19, aged >75 years, with a body mass <60 kg, and with a history of stroke or transient ischemic attack (11) (12) (13) (14) . In order to further achieve platelets inhibition a recent trial has evaluate the superiority of ticagrelor 180 mg LD crushed pills versus integral tables of equal dose in decreasing residual platelet reactivity 1 hour after the administration in ST elevation myocardial infarction patients (15) . However, no trial has evaluated the efficacy of ticagrelor administrated sub lingual in ACS patients.
Objective
To examine chewing versus traditional oral administration of ticagrelor in STelevation Myocardial Infarction (STEMI) patients on platelet reactivity.
Design
The proposed study is a randomized-controlled, conducted among STEMI patients treated with ticagrelor. All patients will be treated with ticagrelor 5. Stent Thrombosis rate at 30-day.
Estimated Enrollment: 100 patients.
Statistical Analysis
The primary and secondary endpoints of the study will be assessed by treatment allocation on an intention-to-treat basis.
The required sample size is based on the primary end point of the study, with the use of a meaningful difference between sublingual and oralloading dose groups of one standard deviation from mean baseline values. Using a 1:1 randmization design, a total of 100 patients will be required to obtain at least 80% power and a 5% one-sided type I error , assuming ≤15% withdrawal rate following enrollment. Student's t-test will be used to test for a difference in prespecified endpoints between the 2 randomized groups in an intention-to-treat bassis.
In the analysis, if the assumption of normality is violated, a nonparametric test (Mann-Whitney test or Wilcoxon signed-rank test) will be performed.
The effect of treatment allocation on the clinical secondary end points will be assessed using Cox proportional hazards regression analysis.
